Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 4/20 | 0.68 |
| ▸ | MC5R | P33032 | 4/20 | 0.68 |
| ▸ | MC4R | P32245 | 2/20 | 0.68 |
| ▸ | MC3R | P41968 | 2/20 | 0.68 |
| ▸ | NMBR | P28336 | 2/20 | 0.59 |
| ▸ | BRS3 | P32247 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256549 | 0.90 | MC4R (0.56) | MC1RMC5RMC4RMC3RNMBR | |
| SCHEMBL7251509 | 0.89 | NMBR (0.66) | MC1RMC5RMC4RMC3RNMBR | |
| SCHEMBL7251347 | 0.88 | NMBR (0.60) | MC1RMC5RMC4RMC3RNMBR | |
| SCHEMBL1231965 | 0.88 | HDAC3 (0.59) | MC1RMC5RMC4RMC3RBRS3 | |
| SCHEMBL7256314 | 0.87 | MC1R (0.63) | MC1RMC5RMC4RMC3RNMBR | |
| SCHEMBL14517026 | 0.84 | NMBR (0.65) | NMBR | |
| SCHEMBL7255933 | 0.84 | NMBR (0.69) | NMBRBRS3 | |
| SCHEMBL1232710 | 0.83 | ECE1 (0.61) | MC1RMC5R | |
| SCHEMBL1232707 | 0.83 | ECE1 (0.61) | MC1RMC5R | |
| SCHEMBL7249995 | 0.83 | NMBR (0.68) | NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195212-A1 | Novel melanocortin receptor agonists and antagonists | MELACURE THERAPEUTICS AB (SE) | 2003-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195212-A1 | Novel melanocortin receptor agonists and antagonists | MC1R, MC5R, MC4R | MC1R 1/4885MC5R 2/4885MC4R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.